scholarly journals Chronic myeloid leukemia with soft tissue infiltration: a case report

2015 ◽  
Vol 24 (1) ◽  
pp. 50-4
Author(s):  
Gaurav Goswami ◽  
Yumkhaibam S. Devi ◽  
Laishram J. Singh
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Fine Needle Aspiration Biopsy ◽  
Symptomatic Relief ◽  
Needle Aspiration ◽  
Total Leukocyte Count ◽  
Liver Size ◽  
Oral Fluids ◽  
Band Form ◽  
Hydroxyurea Treatment

A 27 year old male patient with chronic myeloid leukemia under irregular hydroxyurea treatment presented with a left thigh swelling associated with a dull aching pain. Blood examination revealed a total leukocyte count [TLC] of 125,000/mm3 with 13% metamyelocytes, 8% myelocytes, 1% promyelocytes and 3% band cells. A fine needle aspiration biopsy of the swelling revealed mostly myeloblasts with occasional promyelocytes. He was maintained on tablet hydroxyurea 2g given in divided daily doses along with allopurinol, systemic alkaliser and plenty of oral fluids. Gradual symptomatic relief was achieved over next 2 months with no palpable lump after 3.5 months. TLC was 38,400/mm3 with 1% promyelocytes and myeloblasts and 5% band form. There was reduction in the liver size during this period but no reduction in spleen size. He is currently being maintained on hydroxyurea 2g with other supportive care and has not had any recurrence of symptoms for the last 9 months.

scholarly journals Priapism in Patients Chronic Myeloid Leukemia

2020 ◽  
Vol 2 (4) ◽  
pp. 443-451
Author(s):  
Azhari Gani ◽  
Muhammad Jailani
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hematological Malignancy ◽  
Healing Process ◽  
Philadelphia Chromosome ◽  
Needle Aspiration ◽  
Low Flow ◽  
Hematopoietic Stem ◽  
A Value ◽  
Vascular Obstruction

The aims of this study are to find out the healing process of Priapism in Patients Chronic Myeloid Leukemia. This study used one case of patient which has some complaint, The patients is man with age 29 years old, The patient complained of an enlarged left stomach since 4 months and became heavy in the last 2 weeks, On vital sign examination, compos mentis awareness was found with blood pressure 110/70 mmHg, pulse 80 times per minute, respiratory rate 20 times per minute and temperature 37oC. On the visual analogue scale (VAS) examination showed a value of 4-6 (moderate pain). The result shows that CML is a hematological malignancy characterized by the Philadelphia chromosome and detected clonal expansion of hematopoietic stem cells from ABL BCR examination on chromosomes 9 and 22 which is characterized by an increase in the number of leukocytes with or without enlargement of the spleen. One of the complications of CML is priapism which occurs due to hyperleukocytosis which causes an increase in the viscosity of the blood and this is a major cause of complications of vascular obstruction. Priapism in CML is classified as low-flow (static / ischemic) caused by venocclusiveness which must be treated immediately to restore blood flow to the cavernous corpora by means of needle aspiration.

scholarly journals Studies on Analogues of L-Cysteine and L-Cystine

Blood ◽  
1956 ◽  
Vol 11 (1) ◽  
pp. 19-30 ◽  
Author(s):  
AUSTIN S. WEISBERGER ◽  
LEIF G. SUHRLAND
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Acute Leukemia ◽  
Oral Administration ◽  
Myeloid Leukemia ◽  
Leukocyte Count ◽  
Chemotherapeutic Agents ◽  
Rapid Decrease ◽  
Total Leukocyte Count ◽  
Spleen Size

Abstract Selenium cystine was administered orally to 2 patients with acute leukemia and to 2 patients with chronic myeloid leukemia. In all patients there was a rapid decrease in the total leukocyte count as well as a decrease in spleen size. This effect was observed in patients refractory to other chemotherapeutic agents as well as in the usually resistant types of leukemia. In patients with chronic myeloid leukemia the immature granulocytes disappeared much more rapidly than the mature granulocytes. The most striking and consistent effects were observed in acute leukemia. One patient who had become resistant to 6-mercaptopurine appeared to reacquire sensitivity to this compound after receiving selenium cystine. These effects of selenium cystine on leukocytes correlate with the ability of selenium cystine to decrease the influx of S35 L-cystine by leukemic leukocytes in vitro. Other potentially effective analogues of cystine (or cysteine) may therefore be selected by this technic. No changes were detected in any of the organs attributable to selenium cystine toxicity. The nausea and vomiting associated with the oral administration of selenium cystine was so severe that it was not possible to administer selenium cystine for a sufficient period of time to determine whether an appreciable remission can be obtained in leukemia. Further study is necessary to determine whether selenium cystine has any practical applicability in the chemotherapy of leukemia. Although the mechanism of action of selenium cystine is not known, these striking effects of an analogue of cystine on leukemia are further suggestive of the importance of cystine (cysteine) in the metabolism of leukocytes.

Hydroxyurea treatment for chronic myeloid leukemia during pregnancy

2000 ◽  
Vol 79 (9) ◽  
pp. 803-804 ◽  
Author(s):  
Murat Celiloglu ◽  
Sabahattin Altunyurt ◽  
Bulent Undar
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hydroxyurea Treatment

scholarly journals Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 904-912
Author(s):  
Huma Amin ◽  
Suhaib Ahmed
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Blood Cell ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Cross Sectional Study ◽  
Total Leukocyte Count ◽  
Rt Pcr ◽  
Cross Sectional ◽  
Cell Counts ◽  
Time Of Presentation

Abstract Background Depending on breakpoints of rearrangement different types of BCR–ABL fusion protein can be generated in patients of chronic myeloid leukemia (CML). The aim of this study is to observe frequencies of major transcripts in CML patients by reverse transcriptase polymerase chain reaction (RT-PCR) and their hematological features at the time of presentation. Materials and methods This cross sectional study was performed at Molecular Lab of Riphah International University, Islamabad from January to June 2019. Consecutive peripheral blood samples of 70 newly diagnosed CML patients in chronic phase were analyzed by RT-PCR to detect different BCR–ABL transcripts. Routine blood cell counts were assessed by an automated hematology analyzer. Results All samples expressed typical BCR–ABL rearrangement. Expression of either e14a2 or e13a2 transcript was detected in 38 (54%) and 30 (43%) patients, respectively. Coexpression of e13a2 + e14a2 was found in 2 (3%) patients. The mean total leukocyte count was higher in group expressing e13a2 (P = 0.01). Higher mean platelet count was noted in patients with e14a2 transcript, but this difference was statistically insignificant (P = 0.1). The association of male gender was observed with the group exhibiting e14a2 (P = 0.01). There was no statistically significant association between transcript type and different ranges of age, hemoglobin levels, and platelet and total leukocyte counts (P > 0.05). Conclusion e14a2 transcript was most common transcript in CML patients. Patients exhibiting e13a2 subgroup presented with significantly higher mean white blood cell count at the time of presentation. Significantly higher proportion of male patients was found to express e14a2 transcript over e13a2.

scholarly journals Molecular Diagnosis of Chronic Myeloid Leukemia & Monitoring Response to Different Types of Treatment

2011 ◽  
Vol 5 (1) ◽  
pp. 74-81
Author(s):  
AminaNimma Al-Thwaini ◽  
Manal Ali Abdul-Sahib ◽  
Aladdin Mudhafar Zubair Al-Qasim
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Real Time ◽  
Real Time Pcr ◽  
Myeloid Leukemia ◽  
Fusion Gene ◽  
Philadelphia Chromosome ◽  
Myeloproliferative Disorders ◽  
Lymphocytic Leukemia ◽  
Positive Group ◽  
Hydroxyurea Treatment

Chronic myeloid leukemia (CML) is one of leukemia types which account for 15 % to 20% of all leukemia cases. Patients are presented with splenomegaly, fever, anemia, fatigue, weight loss, and weakness. It is results from reciprocal translocation (9; 22).This abnormality is called Philadelphia (Ph) chromosome and it is detected in 95% of patients with CML, and in 20% of patients with Acute Lymphocytic Leukemia (ALL). "Imatinibmesylate” is the most widely used drug for CML treatment because it targets the abnormal fusion gene. Blood samples were collected from (39) CML patients (19 males and 20 females) from July - November 2009 in The NationalCenter of Hematology/Baghdad. The age range were(8 – 70) years. According to the real time PCR results; the patients were divided into four groups: 1) PCR negative group. 2) PCR positive group on Hydroxyurea treatment 3) PCR positive group on Gleevec® treatment 4) PCR positive group with no treatment (recently diagnosed).Patients were selected randomly. Their RNA was extracted from peripheral blood cells and reverse transcribed into cDNA which was amplified using real time PCR to measure the ratio of BCR-ABL fusion gene in their Philadelphia chromosome. This is to confirm the diagnosis and evaluate the response to the most widely used drugs for CML treatment (Gleevec® 400 mg/d and hydroxyurea 450 mg/d for two months at least). This study excluded CML diagnosis in 10 patients, so other myeloproliferative disorders need to be verified. The group treated with Gleevec® showed a better response than hydroxyurea at the molecular level.Key words: leukemia, chronic myeloid leukemia, polymerase chain reaction, real time PCR, BCR-ABL, quantitative PCR, hydroxyurea, imatinibmesylate, Philadelphia chromosome, tyrosine kinase.

Uncommon long-term survival in a patient with chronic myeloid leukemia

2009 ◽  
pp. 1-2
Author(s):  
Fabio Stagno ◽  
Paolo Vigneri ◽  
Vittorio Del Fabro ◽  
Stefania Stella ◽  
Salvatore Berretta ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document